Denali director granted RSUs and stock options

Denali Therapeutics director David P. Schenkein reported new equity awards.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Denali Therapeutics director David P. Schenkein reported new equity awards. He received 6,408 Restricted Stock Units, each representing a contingent right to one share of common stock. These RSUs vest in full on the earlier of one year from grant or the day before the next annual stockholder meeting.

He also received a stock option for 19,226 shares at an exercise price of $19.66 per share, with the same vesting schedule. After these grants, he directly holds 21,665 common shares, and additional common shares are held indirectly through the David P. Schenkein 2004 Revocable Trust and the Amy P. Schenkein 2004 Revocable Trust.

Insider Trade Summary

Grant/Award: 25,634 shares

Grant/Award 4 txns

Insider Schenkein David P

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	19,226	$0.00	$0.00
Grant/Award	Common Stock	6,408	$0.00	$0.00
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 19,226 contracts (Direct); Common Stock — 21,665 shares (Direct); Common Stock — 57,464 shares (Indirect, See footnote)

Footnotes (5)

F1. Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
F2. Includes 6,408 unvested RSUs.
F3. The shares are held of record by the David P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee.
F4. The shares are held of record by the Amy P. Schenkein 2004 Revocable Trust, for which the Reporting Person's spouse serves as a trustee.
F5. 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

Key Figures

RSU grant: 6,408 RSUs Stock option grant size: 19,226 shares Stock option exercise price: $19.66 per share +4 more

7 metrics

RSU grant 6,408 RSUs Director equity award; each RSU equals one common share

Stock option grant size 19,226 shares Stock option (right to buy) underlying common shares

Stock option exercise price $19.66 per share Exercise price for newly granted stock option

Option expiration June 3, 2036 Expiration date of the stock option grant

Direct common stock holdings 21,665 shares Common shares held directly after transactions, including 6,408 unvested RSUs

Trust holding – David P. Schenkein 2004 Revocable Trust 31,232 shares Common shares held of record by revocable trust

Trust holding – Amy P. Schenkein 2004 Revocable Trust 26,232 shares Common shares held of record by spouse’s revocable trust

Key Terms

Restricted Stock Unit ("RSU"), contingent right, Revocable Trust, Stock Option (right to buy), +1 more

5 terms

Restricted Stock Unit ("RSU") financial

"Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right..."

contingent right financial

"and a contingent right to receive one share of common stock of the Issuer."

Revocable Trust financial

"The shares are held of record by the David P. Schenkein 2004 Revocable Trust..."

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

Stock Option (right to buy) financial

"security_title": "Stock Option (right to buy)""

vesting financial

"100% of the RSUs shall vest upon the earlier of (i) the one year anniversary..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Denali Therapeutics (DNLI) director David P. Schenkein receive?

David P. Schenkein received 6,408 Restricted Stock Units and a stock option covering 19,226 shares of Denali Therapeutics common stock. Both awards have a zero grant price, with the option exercisable at $19.66 per share after vesting, reflecting routine director compensation.

How do David P. Schenkein’s new RSUs in Denali Therapeutics (DNLI) vest?

The 6,408 RSUs granted to David P. Schenkein vest 100% on the earlier of one year from the grant date or the day before Denali Therapeutics’ next annual meeting of stockholders. Each vested RSU represents the right to receive one share of common stock.

What are the key terms of David P. Schenkein’s new stock option in Denali Therapeutics (DNLI)?

David P. Schenkein received a stock option for 19,226 shares of Denali Therapeutics common stock with a $19.66 exercise price. All shares under the option vest on the earlier of one year from grant or the day before the next annual stockholder meeting, and expire on June 3, 2036.

How many Denali Therapeutics (DNLI) shares does David P. Schenkein hold directly after these grants?

Following the reported grants, David P. Schenkein directly holds 21,665 shares of Denali Therapeutics common stock. This figure includes 6,408 unvested RSUs, which will settle into shares only as they vest under the stated one-year or pre–annual-meeting vesting schedule.

What indirect holdings in Denali Therapeutics (DNLI) are associated with David P. Schenkein?

Indirect holdings include shares held by the David P. Schenkein 2004 Revocable Trust and the Amy P. Schenkein 2004 Revocable Trust. The Form 4 shows 31,232 shares and 26,232 shares, respectively, following the reported date, with David or his spouse serving as trustee for these trusts.

Is David P. Schenkein’s Denali Therapeutics (DNLI) Form 4 a market purchase or sale?

The Form 4 reports equity grants, not open-market purchases or sales. It shows an award of RSUs and a stock option as part of director compensation, with no reported buying or selling transactions in the market during the period covered by this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/05/2026 - 04:45 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schenkein David P

(Last)

(First)

(Middle)

C/O DENALI THERAPEUTICS INC.

161 OYSTER POINT BLVD.

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Denali Therapeutics Inc. [ DNLI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/03/2026		A		6,408⁽¹⁾	A	$0	21,665⁽²⁾	D
Common Stock								26,232	I	See footnote⁽³⁾
Common Stock								31,232	I	See footnote⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$19.66	06/03/2026		A		19,226		⁽⁵⁾	06/03/2036	Common Stock	19,226	$0	19,226	D

Explanation of Responses:

1. Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

2. Includes 6,408 unvested RSUs.

3. The shares are held of record by the David P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee.

4. The shares are held of record by the Amy P. Schenkein 2004 Revocable Trust, for which the Reporting Person's spouse serves as a trustee.

5. 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

Remarks:

	/s/ Tyler Nielsen, by power of attorney	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR